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Preeclampsia is a condition associated with high rates of maternal-fetal morbidity and
mortality. It usually occurs in 3–10% of nulliparous women and 18% of previously
affected women. Different lines of evidence have demonstrated the role of the father
in the onset of preeclampsia. The placenta is the cornerstone of preeclampsia and
poses important paternal genetic determinants; in fact, the existence of a “paternal
antigen” has been proposed. Nulliparity is a well-known risk factor. Change of partner
to a woman without history of preeclampsia increases the risk; however, this change
decreases in women with history of the condition. High interval between pregnancies,
short sexual intercourse before pregnancy, and conception by intracytoplasmic sperm
injection suggest a limited exposure to the so-called paternal antigen. A man who was
born from a mother with preeclampsia also increases the risk to his partner. Not only
maternal but also paternal obesity is a risk factor for preeclampsia. Fetal HLA-G variants
from the father increased the immune incompatibility with the mother and are also
significantly associated with preeclampsia in multigravida pregnancies. An analysis of a
group of Swedish pregnant women showed that the risk for preeclampsia is attributable
to paternal factors in 13% of cases, which could be related to genetic interactions with
maternal genetic factors. This review aimed to evaluate the evidences of the father’s
contribution to the onset of preeclampsia and determine the importance of including
them in future studies.
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BACKGROUND
Preeclampsia is a condition in pregnant women associated with high rates of maternal and fetal
morbidity and mortality worldwide. This disease is characterized as a systemic syndrome with
de novo hypertension occurring after 20 weeks of gestation as well as proteinuria (300 mg in 24 h)
(NHBPEP, 2000). In 2013, the Task Force on Hypertension in Pregnancy established new diagnostic
criteria for hypertension in pregnancy.
Preeclampsia is related to deficient placental implantation, with multisystem consequences
(generalized endotheliosis) in the mother (Roberts and Hubel, 2009). Its incidence in industrialized
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countries ranges from 3 to 5% (Stone et al., 1995; Dahlstrom et al.,
2006; Wallis et al., 2008), which reaches up to 16% in Nigeria
(Osungbade and Ige, 2011). The frequency of maternal and
perinatal deaths in Mexico is 34 and 33%, respectively (Peralta
Pedrero et al., 2006).
Preeclampsia is classified as mild and severe and can
complicate to hemolysis, elevated liver enzymes, and low platelet
count (HELLP) syndrome and eclampsia (Geller et al., 2004).
The pathophysiology of preeclampsia is characterized by
placental hypoxia and/or ischemia leading to overexpression
of hypoxia-inducible factor 1 (HIF1), which in turn increases
the expression of the soluble isoform of vascular endothelial
growth factor (sFlt) (Nevo et al., 2006). Hypoxic placenta also
releases the soluble endoglin, antagonizing the production of
endothelial nitric oxide synthase (eNOS) through sequestering
of transforming growth factor beta1 (TGFb1) (Sandrim et al.,
2008). In addition, the proangiogenic factors such as the placental
growth factor (PIGF) and vascular endothelial growth factor
(VEGF) (Reuvekamp et al., 1999). Together, they can trigger the
antiangiogenic state in the mother, which resulted in generalized
endothelial dysfunction.
Risk factors for disease development include nulliparity,
pregnancy with multiple products, previous history of
preeclampsia, vascular and connective tissue diseases, maternal
age of >35 years, Afro-American ethnicity, preexistent renal
disease, arterial hypertension, type 2 diabetes, and obesity (Eiland
et al., 2012).
Previous studies on preeclampsia have considered the
mother’s participation almost exclusively. However, the placenta
is a transient biparental organ with maternal and paternal
contributions. In this way, changes on the expression profile
of genes involved in the metabolism and transport in the
placenta depend on various maternal and paternal genetic
profiles (Zusterzeel et al., 2002; Dekker et al., 2011).
Increasing evidence has demonstrated the father’s role in the
onset of preeclampsia. In Astin et al. (1981) reported a case of a
man who fathered two consecutive women who developed severe
preeclampsia and passed away, suggesting the existence of a “fatal
father factor.”
The risk of preeclampsia is genetically attributable to the
mother (35%), fetus (20%), and couple (13%) (Cnattingius et al.,
2004). Women and men who were born from a pregnancy
with preeclampsia are at higher risk to have a baby, result
of a preeclamptic pregnancy (Esplin et al., 2001). The change
of partner increases the risk for preeclampsia in 1.6%, which
increases up to 2.9% in a woman whose second pregnancy is
the result of union with a man who has had a previous partner
with preeclampsia (Lie et al., 1998). Change of partner plays
a predisposing or protective role, depending of the presence
or absence of the disease in the first pregnancy (Wikström
et al., 2012). The presence of fetal variants of HLA-G from the
father and those outside the mother generate a paternal-fetal
susceptibility component for the development of preeclampsia
(Tan et al., 2008).
Paternal genetic material plays an important role for the
onset of preeclampsia. A triploid (69 XXX) partial mole, with
paternal isodisomy in the placenta and a disomic fetus, increases
preeclampsia-like symptoms at 19 weeks of gestation (Yoneda
et al., 2013). Although preeclampsia is a human-specific disorder,
animal models of the disease have been created to show the role
of the paternal genetic factors. A female transgenic mouse for
human angiotensinogen gene was mated with a male transgenic
mouse for human renin gene, originating a preeclampsia-like
syndrome (Takimoto et al., 1996).
In this review, we aimed to describe different lines of evidence
regarding the paternal contribution on preeclampsia.
EPIDEMIOLOGICAL AND CLINICAL
EVIDENCE
Preeclampsia has been traditionally considered as a disease
during first pregnancies; however, an early study by Need (1975)
showed that a woman, pregnant by different fathers, had a healthy
twin pregnancy with the first men, but severe preeclampsia
occurred in the second one. The analysis of 34,201 patients
revealed the presence of 47 multigravid patients with severe
preeclampsia. A new partner was demonstrated in 13 among
them (19.1%), and significant difference was observed than those
in the control group (p < 0.01) (Feeney and Scott, 1980).
Ikedife (1980) showed that change of partners was observed
in 34 (74%) out of 46 multiparous patients with eclampsia.
A woman with three different husbands presented preeclampsia
only in the first pregnancy of the second and third spouses.
Therefore, preeclampsia is not just a primiparous woman disease
but also a condition related to the first pregnancy with a
particular partner (Chng, 1982). The Guadeloupe study revealed
an increased change of partner in multiparous women who
were affected with preeclampsia (Robillard et al., 1993). The
same group demonstrated that the incidence of preeclampsia was
11.9% among primigravidae, 4% among multigravidae without
a change of paternity, and 24% among multigravidae with a
new partner; however, these numbers depend on the duration of
sexual cohabitation before conception (Robillard et al., 1994).
When evaluating paternal vs. maternal half-sisters with
preeclampsia, Lie et al. (1998) found an increased risk for
the disease in the former. Likewise, they showed that 13% of
primiparous mothers with preeclampsia had recurrence in the
second pregnancy, decreasing the influence of partner’s change
(11.8%), which is opposite in mothers without preeclampsia in
their first pregnancy (Lie et al., 1998).
The same results were obtained by Li and Wi (2000). Pipkin
(2001) observed that partner’s change increases the risk for
preeclampsia occurrence in primiparous women.
A woman pregnant by a partner who previously fathered
a woman with preeclampsia was highly at risk to develop the
disease. In 2004, Cnatinggius et al. evaluated three different
scenarios: (1) mothers without preeclampsia and no partner
change (control group); (2) mothers with previous preeclampsia,
current preeclampsia, and change of spouse who was not
fathered by a previous couple with preeclampsia; and (3)
mothers with preeclampsia and change of couple who fathered
another woman with preeclampsia. The maternal effect was 45%,
meanwhile the paternal one was 10% (Cnattingius et al., 2004).
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Conversely, Chigbu et al. (2009) evaluated two groups of Nigerian
women with and without change of partner in their second
pregnancy and found no differences for the development of
preeclampsia.
Marti and Herrmann (1977) found that preeclampsia is
associated with shorter exposure to spermatozoa in younger
women and more frequent use of barrier contraceptive methods.
Therefore, the authors coined the term “immunogestosis” to
denote the immune nature of preeclampsia. The use of barrier
contraceptive methods was significantly higher in women
with preeclampsia compared to healthy women [odds ratio
(OR) = 2.48], and the number of sexual contacts was inversely
related to the risk of preeclampsia (Klonoff-Cohen et al., 1989).
Conversely, Mills et al. (1991) and Ness et al. (2004) found no
differences in the use of barrier contraceptive methods between
women with and without preeclampsia.
Shorter sexual intercourse increases the shorter antigenic
seminal exposure (Beer, 1989). The risk of pregnancy-induced
hypertension (PIH) was increased when conception is within
12 months of sexual cohabitation: 40% in 0–4 months,
23% in 5–8 months, 15% in 9–12 months, and 5% after
12 months (Robillard et al., 1994). The same author compared
patients with simple PIH versus those with preeclampsia and
eclampsia and observed that the sexual cohabitation times are
shorter (9.5 months) compared to those of unaffected women
(26.3 months) (Robillard and Hulsey, 1996). Koelman et al.
(2000) found a lower frequency of oral sex in women with
preeclampsia compared to healthy pregnant women (p = 0.0003),
suggesting a protective role. The authors report lower amounts
of soluble HLA A and HLA B in the seminal fluid, in partners
of preeclamptic women (Koelman et al., 2000). In Robertson
et al. (2003) proposed how repeated semen exposure protects
preeclampsia, based on four lines of evidence: (1) the semen
contains antigens shared by the conception; (2) after the seminal
contact, the maternal mucosa can mount a regulated immune
response to semen antigens; (3) semen contains among others,
high amounts of TGFb that can inhibit type 1 immunity; and
(4) TGFb-dependent changes in T-lymphocytes allow a hypo-
responsiveness to paternal antigens. The exposure to seminal
fluid through the vagina is inversely correlated with the risk of
preeclampsia occurrence, whereas the oral exposure to seminal
fluid has no effect on disease development (Saftlas et al., 2014).
A clear increase in the frequency of preeclampsia when
the father (OR = 2.1) and mother (OR = 3.3) are products
of preeclampsia-complicated pregnancies has been observed;
however, this study did not consider the changes of paternity
(Conde-Agudelo, 2001). In men who were born after a pregnancy
complicated by preeclampsia, the risk in the first pregnancy was
moderately increased compared with men who were born after a
pregnancy without preeclampsia (OR = 1.5, 1.3–1.7).
This observed risk increases when severe or early preeclampsia
is considered (OR = 1.9, 1.4–2.5) (Skjaerven et al., 2005).
Lie (2007) found similar numbers: fathers who came from a
preeclamptic pregnancy had a 1.5-fold risk [95% CI 1.3–1.7] of
fathering a preeclamptic pregnancy.
Since, Need et al. (1983) reported a significantly higher
frequency of preeclampsia in women with abortions (15.7%)
than those with normal pregnancy (4.7%). They also found
that azoospermia and oligospermia present a lower frequency
of preeclampsia of 8.7 and 13.6%, respectively, which could be
related to the minimal antigenic sperm exposure. The frequency
of preeclampsia was higher in the donor insemination program
than those in the father insemination program (OR = 1.20,
95%) (Smith et al., 1997). Hoy et al. (1999) revealed a higher
frequency of preeclampsia in donor-inseminated women vs.
natural-inseminated women (OR = 1.4, 95% CI). In Salha
et al. (1999) compared 72 infertile women subjected to sperm,
ovum, or embryo donation, with the same number of pregnant
women through insemination with their own ovum or partner’s
spermatozoa (control group). Fourteen patients developed
preeclampsia, 13 of whom belong to the group of donated
gametes and 1 to the control group. Kyrou et al. (2010) found a
marginally significant (p= 0.05) higher frequency of preeclampsia
in women conceiving by a sperm donor compared to partners
in spermatozoa insemination. The type of spermatozoa and
number of previous insemination cycles were the variables that
influenced the risk of preeclampsia (p = 0.012); in fact, the
authors observed that the fewer the number of the insemination
cycles, the higher the risk of preeclampsia (Kyrou et al., 2010).
A recent meta-analysis of seven studies showed the association
with preeclampsia in women conceiving with donor sperm
(OR = 1.63) (González-Comadran et al., 2014). Another study
evaluated the risk of preeclampsia in infertile women subjected
only to sperm donation via intrauterine insemination (IUI) or
in vitro fertilization (IVF), compared to those with primary
sperm donation (IUI or IVF) followed by egg donation. A higher
frequency of preeclampsia in the latter was observed; therefore,
the authors conclude that double gamete donation is associated
with increased risk for preeclampsia (Bartal et al., 2018).
The aforementioned studies support the theory of the
immunological basis of preeclampsia.
IMMUNOLOGICAL EVIDENCE
Preeclampsia is a state in which alloantigen (placenta of paternal
origin) must be recognized to avoid rejection (Saito et al.,
2007). Trophoblast cells must express paternal alloantigens
that must be recognized by the mother’s immune system.
Extravillous trophoblast express different HLA-C, E, F, and G
(Hackmon et al., 2017). HLA-C is the ligand of immunoglobulin-
like receptors (KIR) that are expressed in decidual natural
killer (NK) cells (Sharkey et al., 2008). HLA-C and KIR
are polymorphic; therefore, many maternal/paternal different
combinations are possible. Two KIR haplotypes exist A and
B, with the latter stimulating the expression of chemokines
and angiogenic cytokines, promoting trophoblast invasiveness.
Therefore, haplotype B could be protective for preeclampsia
(Redman and Sargent, 2010). Seminal priming triggers a cascade
of events for placental recognition or rejection. Seminal fluid
contains high amounts of TGF-b that induces T-regulatory cells
(Treg); these cells modulate immune responses in an antigen-
specific way. Therefore, the effects of HLA-C/KIR interaction
plus the seminal priming activity of TGF-b could in some
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extent explain the immune nature of father’s involvement in
preeclampsia (Redman and Sargent, 2010).
The immune nature of preeclampsia was observed by Need
(1975), who demonstrated histoincompatibility in a mother who
developed preeclampsia with her second partner through the
evaluation of HL-A typing. In Feeney et al. (1977) found a
lower incidence of preeclampsia in previously blood-transfused
women, compared with the same number of non-transfused
primigravidas. A similar effect is observed in patients with
kidney transplantation (Feeney et al., 1977). In the same year,
Marti and Herrmann, (1977) found a correlation between
the number of exposures to semen and lower frequency of
preeclampsia; they coined the term immunogestosis to explain
both, the immunologic tolerance and immunologic enhancement
that abrogates immunoreaction against paternal and fetal
histocompatibility antigens.
Birkeland and Kristofferson (1979) evaluated the immune
response in mothers with and without preeclampsia and found
no leukocyte antigens against the father in women with normal
pregnancies, meanwhile these antigens were identified in one
woman with severe preeclampsia. The evaluation of HLA A, B,
and DR in women with severe and mild preeclampsia as well
as their husbands and babies revealed a higher frequency of
DR4 in all family members in severe preeclampsia (Kilpatrick
et al., 1987). However, HLA A, B, and C are expressed in low
amounts in the trophoblast, and HLA-G protein is exclusively
expressed in trophoblast cells in high amounts. The evaluation
of 1597del/C allele was not associated with preeclampsia
(Aldrich et al., 2000). Three polymorphisms in HLA-G were
evaluated in 68 primigravida trios, but were not associated with
preeclampsia (Bermingham et al., 2000). The evaluation of 15
alleles in 4 exons of HLA-G in 155 family triads showed an
overrepresentation of a homozygous HLA-G genotype in 40
pre-eclamptic offspring compared to 70 controls (p = 0.002)
among primiparous women; further analyses suggested that
the differences between pre-eclamptic cases and controls were
primarily accomplished by a different transmission from the
father of a 14 bp deletion/insertion polymorphism in the 3′UTR
region (14 bp del/in) (p = 0.006) (Hylenius et al., 2004). In Tan
et al. (2008) observed a significant association between paternally
inherited HLA-G allele G∗0106 in the fetus and an increased
risk for preeclampsia, but only in multigravid pregnancies. The
14 bp del/in was evaluated in three different combinations:
mother/offspring, father/offspring, and couples; heterozygosity
in the mother plus double insertion in babies was significantly
higher in severe early-onset preeclampsia (p = 0.023), and the
frequency of double deletion in both the father and baby was
lower in severe early-onset preeclampsia (p = 0.024). The analysis
of couples did not reveal significant differences between cases
and controls (Zhang et al., 2012). A recent meta-analysis of 1,625
cases and 2,145 controls in all members of the triads evaluated
the influence of 14 bp del/in in the onset of preeclampsia; the
results did not reveal the association with the disease in offspring,
mothers, or fathers. A stratification showed the association of
14 bp del/in with preeclampsia in European Caucasian offspring,
but not found in African descent population (Pabalan et al.,
2015).
Semen is not sterile, and its microbes have also been
considered as a potential cause of preeclampsia. Repeated
exposure to semen seems to create a memory protecting women
from preeclampsia and the same could be possible in the case of
semen microbes. Therefore, common elements of preeclampsia
and infections such as Galectin13, Toll-like receptors, and
antiphospholipid syndrome are found (Kenny and Kell, 2018).
GENETIC EVIDENCE
The genetic nature of preeclampsia has also been evaluated
through (1) familial cases, (2) twin studies, (3) consanguinity
studies, (4) candidate gene evaluation, and (5) linkage analysis.
Genes are involved in different pathophysiological mechanisms
involved in preeclampsia. Genetic studies that included
mother/father/children triads, which allow to determine the sole
or joint contribution for preeclampsia, were limited.
The evaluation of thrombophilic genes methyle
netetrahydrofolate reductase (MTHFR) and FVL in 92
mother/father/child triads revealed an increased risk only
in mothers carrying two mutated copies of MTHFR and one
mutated allele in FVL. Therefore, the risk of preeclampsia is not
increased in the presence of fetal MTHFR or FVL mutations
(Vefring et al., 2004). In van Dijk et al. (2010) observed a
methylated paternal copy of STOX1 gene and an unmethylated
active maternal copy of the gene. Maternal transmission of this
gene has been demonstrated in preeclampsia (van Dijk and
Oudejans, 2011). The evaluation of GSTP1, eNOS, and LPL genes
in 167 preeclamptic and control triads in a Greek cohort, which
significantly demonstrated higher frequencies of Val105 allele
(GSTP1) and Glu298Asp (eNOS) in control vs. preeclamptic
groups in mothers, fathers, and child. The -93 polymorphism
(LDL) was higher in preeclampsia only in mothers, but not in
fathers or children. The transmission disequilibrium test revealed
no differences in the rate of transmission of the studied common
vs. mutated alleles (Pappa et al., 2011).
In Zhou et al. (2013) found a significant association of C4599A
polymorphism in AGTR2 gene with preeclampsia in mothers
with body mass index (BMI) of ≥25 kg/m2 in their partners
and studied children. Galaviz-Hernandez et al. (2016) evaluated
the polymorphism rs5370 of EDN1 gene in mothers with
preeclampsia and their partners, showing a significant negative
association with the disease in case of fathers (OR = 0.42; CI 95%,
0.18–0.94, p = 0.034), which was strengthened after adjusting the
paternal protective factors. The evaluation of two polymorphisms
in SOD1 (+35A/C) and SOD2 (Ala16Val (C/T) genes in 698
mother/father/infant triads revealed a significant association with
preeclampsia in fathers with Ala16Val (TT genotype) [OR = 2.77
(1.32–5.81), p = 0.007]. This study revealed essentially the
same risk for preeclampsia in both combined TT genotypes in
mothers and fathers [OR = 6.80 (2.32–19.95), p < 0.001] and
mother/father/infant triads [OR = 6.46 (2.16–19.31), p < 0.001]
(Luo et al., 2018). Polymorphisms in the thrombophilic genes
factor V Leiden, prothrombin, and MTHFR were evaluated
in women, fetus, and fathers as risk factors for pregnancy-
associated complications, including preeclampsia. The authors
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found significant differences between cases and controls in
maternal Factor V and fetal MTHFR, but no differences on any
of the polymorphisms analyzed in the father’s group (Nevalainen
et al., 2018).
CONCLUSION AND PERSPECTIVES
Epidemiological, clinical, immunological, and genetic evidences
supported the contribution of fathers in the onset of
preeclampsia. Despite this, few studies were intended to evaluate
the spouses’ role. In this way, the evaluation of paternal-
derived immune and genetic materials was performed in order
to identify the risk and prognostic markers of preeclampsia.
Recent advances in placental epigenetics, along with the use of
OMICS tools, ensure the identification of molecular markers
associated with the role of fathers in the development of
preeclampsia.
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